Loading data
CTXRNasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development expense | 9.16 m USD | 11.91 m USD | 14.82 m USD | 17.66 m USD |
| Operating profit | -38.53 m USD | -42 m USD | -36.73 m USD | -33.32 m USD |
| Profit before tax | -38.68 m USD | -38.85 m USD | -31.97 m USD | -33.06 m USD |
| Income tax expense | 1.06 m USD | 576 k USD | 576 k USD | 576 k USD |
| Net income (reported basis) | -37.43 m USD | -40.19 m USD | -33.69 m USD | -33.64 m USD |
| Net income attributable to common shareholders | -37.43 m USD | -40.19 m USD | -33.69 m USD | -33.64 m USD |
| Basic earnings per share | -3.38 USD/share | -5.97 USD/share | -5.57 USD/share | -0.23 USD/share |
| Diluted earnings per share | -3.38 USD/share | -5.97 USD/share | -5.57 USD/share | -0.23 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.